Presbia (LENSF) 10-K 28 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 21, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	LENS
Entity Registrant Name	PRESBIA PLC
Entity Central Index Key	1,591,096
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,371,445
Entity Public Float			$ 30,140,000

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash	$ 21,749	$ 138
Accounts receivable	116	25
Inventory	430	378
Prepaid expenses and other current assets	242	122
Total current assets	22,537	663
Property and equipment, net	775	747
Intangible assets	32	46
Other assets	63	886
Total assets	23,407	2,342
Current liabilities
Accounts payable	736	1,882
Due to related parties	55	12
Other current liabilities	569	700
Total current liabilities	1,360	2,594
Payable due to the Parent		417
Deferred rent	22	37
Total liabilities	$ 1,382	$ 3,048
Commitments and contingencies (note 12)
Shareholders' equity (deficit)
Common Ordinary Shares	$ 13
Deferred Ordinary shares	54	$ 54
Additional paid-in capital	77,505	36,626
Accumulated deficit	(55,547)	(37,386)
Total shareholders' equity (deficit)	22,025	(706)
Total liabilities and shareholders’ equity (deficit)	$ 23,407	$ 2,342

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2015$ / sharesshares	Dec. 31, 2015€ / sharesshares	Dec. 31, 2014$ / sharesshares	Dec. 31, 2014€ / sharesshares
Statement Of Financial Position [Abstract]
Common ordinary shares, par value | $ / shares	$ 0.001		$ 0.001
Common ordinary shares, shares authorized	350,000,000	350,000,000	350,000,000	350,000,000
Common ordinary shares, shares issued	13,355,477	13,355,477	0	0
Common ordinary shares, shares outstanding	13,355,477	13,355,477	0	0
Deferred ordinary shares, par value | (per share)	$ 1.35	€ 1	$ 1.35	€ 1
Deferred ordinary shares, shares authorized	39,994	39,994	40,000	40,000
Deferred ordinary shares, shares issued	39,994	39,994	40,000	40,000
Deferred ordinary shares, shares outstanding	39,994	39,994	40,000	40,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenues	$ 153	$ 161
Cost of goods sold	163	61
Gross profit (loss)	(10)	100
Operating expenses:
Research and development	7,935	4,243
Sales and marketing	2,706	1,652
General and administrative	7,479	7,577
Total operating expenses	18,120	13,472
Operating loss	(18,130)	(13,372)
Interest expense		2,288
Other (income) expense	12	(6)
Loss before income tax provision	(18,142)	(15,654)
Income tax provision	19	10
Net loss	(18,161)	(15,664)
Total comprehensive loss	$ (18,161)	$ (15,664)
Net loss per share - basic and diluted	$ (1.40)	$ (1.71)
Weighted average, shares outstanding - basic and diluted	12,945,968	9,166,667

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Deferred Shares [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2013	$ (8,882)			$ 12,840	$ (21,722)
Capitalization of amounts due to Parent pursuant to 2015 Debt Conversion of Presbia Holdings	23,473			23,473
Stock-based compensation (including allocation from the Parent)	313			313
Issuance of Euro shares related to formation of Presbia PLC	54		$ 54
Issuance of Euro shares related to formation of Presbia PLC, shares			40,000
Net loss	(15,664)				(15,664)
Balance at Dec. 31, 2014	$ (706)		$ 54	36,626	(37,386)
Balance, shares at Dec. 31, 2014	40,000		40,000
Capitalization of amounts due to Parent pursuant to 2015 Debt Conversion of Presbia Holdings	$ 1,559			1,559
Initial public offering, net of issuance costs	36,844	$ 13		36,831
Initial public offering, net of issuance costs, shares		13,333,334
Stock-based compensation (including allocation from the Parent)	2,306			2,306
Cancellation of deferred shares pursuant to distribution of Parent's assets, shares			(6)
Issuance of restricted stock, shares		22,143
Bonus payments by Parent on behalf of Parent	183			183
Net loss	(18,161)				(18,161)
Balance at Dec. 31, 2015	$ 22,025	$ 13	$ 54	$ 77,505	$ (55,547)
Balance, shares at Dec. 31, 2015		13,355,477	39,994

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flow from operating activities:
Net loss	$ (18,161)	$ (15,664)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and Amortization	173	138
Inventory provisions	169	61
Loss on disposal of fixed assets	12
Write-off of deferred offering costs		3,369
Stock-based compensation (including allocation from Presbia Holdings)	2,306	313
Non-cash interest expense on funding from the Parent	1	2,288
Non-cash operating expenses allocated from the Parent	183	183
Changes in operating assets and liabilities:
Accounts receivable	(91)	(5)
Inventory	(222)	(239)
Prepaid expenses and other current assets	(120)	23
Other assets	9	(9)
Accounts payable and other current liabilities	44	136
Income taxes payable	16	8
Deferred rent	(15)	4
Due to related parties	43	(120)
Net cash used in operating activities	(15,653)	(9,514)
Cash flow from investing activities:
Website development costs		(46)
Purchase of property and equipment	(196)	(133)
Net cash used in investing activities	(196)	(179)
Cash flow from financing activities:
Proceeds from issuance of ordinary shares upon initial public offering, net of underwriting costs	38,750
Deferred offering costs	(2,431)	(2,151)
Capitalization of Presbia PLC		54
Funding from the Parent	1,141	11,344
Net cash provided by financing activities	37,460	9,247
Net increase(decrease) in cash	21,611	(446)
Cash balance at beginning of period	138	584
Cash balance at end of period	21,749	138
Supplemental disclosure of cash flow information:
Cash paid for income taxes	3	6
Supplemental disclosures of non-cash investing and financing activities:
Deferred offering costs included in accounts payable and other current liabilities		1,365
Allocated operating expenses funded by the Presbia Holdings		183
Capitalization of amounts due to Parent per 2014 and 2015 Debt Conversions	$ 1,559	$ 23,473

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	(1) Basis of Presentation and Description of the Business Presbia PLC (the “Company” or “Presbia PLC”), an Irish public limited company, was formed on February 6, 2014 through the issuance of 40,000 shares for 40,000 Euro (approximately $54,000) for the purpose of consummating an initial public offering (“IPO”) of its ordinary shares. Presbia PLC’s ultimate controlling shareholder, Presbia Holdings (the “Parent”), was organized in the Cayman Islands in 2007 as an exempted company with limited liability. On October 21, 2013, the Parent completed a restructuring (the “2013 Restructuring”) which involved the formation on September 13, 2013 of an interim holding company, Presbia Ireland, Limited, and the contribution by the Parent of 100% of its direct and indirect ownership interests in its business, assets and subsidiaries to Presbia Ireland, Limited. On November 30, 2014, Presbia Holdings converted all the remaining indebtedness owed to Presbia Holdings by certain subsidiaries of Presbia Ireland, Limited at that time to equity (“2014 Debt Conversion”). In the 2014 Debt Conversion, approximately $23.5 million of outstanding intercompany debt owed to Presbia Holdings was converted to equity of Presbia Ireland, Limited. On January 14, 2015, Presbia Holdings converted all the remaining indebtedness owed to Presbia Holdings by a subsidiary of Presbia Ireland, Limited at that time to equity (the “2015 Debt Conversion”) in the amount of approximately $1.6 million. On January 14, 2015, the Parent contributed all the share capital in issue in Presbia Ireland, Limited to Presbia PLC (the “2015 Capital Contribution”) in exchange for 9,166,667 ordinary shares of Presbia PLC. The aggregate 9,166,667 ordinary shares of Presbia PLC have been reflected as issued and outstanding as of the earliest date of the periods presented for purposes of computation of basic and diluted net loss per share. On February 3, 2015, Presbia PLC completed its initial public offering (“IPO”) of 4,166,667 of its ordinary shares at a price to the public of $10.00 per ordinary share and commenced trading on The NASDAQ Global Market under the symbol LENS. The Parent acquired 500,000 ordinary shares from the public offering. The net proceeds from the IPO consisted of aggregate gross proceeds of approximately $41.7 million less underwriting discounts and commissions of approximately $2.9 million and other issuance costs of approximately $2.0 million resulting in net proceeds of approximately $36.8 million. On August 3, 2015, Presbia Holdings completed the distribution of its holdings of 9,666,667 ordinary shares of Presbia PLC to its ordinary shareholders for the purpose of dissolving Presbia Holdings on November 25, 2015 and ceasing to be the Parent of Presbia PLC. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC, Presbia Ireland, Limited, organized in Ireland, Presbia Investments organized in the Cayman Islands and Presbia USA, Inc., and OPL, LLC. Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation. All amounts are shown in U.S. dollars. The Company, which began to be formed on June 29, 2007, has developed and is marketing a surgical solution to the age-related vision condition known as presbyopia. The Company’s primary objectives have been twofold: (1) achieve commercial success in those parts of the world where the Company’s surgical procedure has been approved by regulatory agencies and (2) successfully apply to the United States Food and Drug Administration (the “FDA”) for the authorization to market and manufacture the surgical procedure in the United States. Other than the FDA clinical trials that begun in 2014 and will continue to at least 2018, this procedure is currently not authorized by the FDA and may not be manufactured, sold, distributed or surgically performed on any individual in the United States. The Company’s principal revenue generating activity is the sale of the Company’s microlens to approved ophthalmologist physicians who, in turn, perform the surgical procedure on their patient base. Presbia is authorized to sell, market and perform this procedure in 40 countries through its wholly-owned Dutch subsidiary, Presbia Cooperatief U.A. Activities to-date have consisted primarily of research and development and expansion of its commercial activities in selected markets outside the United States Stock-based compensation expenses recognized by the Parent that were incurred to benefit the Company have been allocated to the Company (see Note 9). The financial information in these statements may not include all of the expenses that would have been incurred had the Company been a separate, stand-alone publicly traded entity. Liquidity The Company has incurred significant operating losses since inception and has relied on funding from its Parent to fund our operations prior to its initial public offering concluded on February 3, 2015. At December 31, 2015, the Company has an accumulated deficit of $55.5 million. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its product and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Management expects that existing cash as of December 31, 2015 of $21.7 million will be sufficient to fund the Company’s operations through December 31, 2016.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management makes estimates and assumptions that are included in the consolidated financial statements and accompanying notes. The actual results may differ from those estimates. Segment Information In accordance with Accounting Standard Codification (“ASC”) 280-10-50, Segment Reporting, operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Since 2013, the Company has viewed and managed its operations and business as one segment through its wholly-owned Dutch subsidiary, Presbia Cooperatief U.A. and its wholly-owned Irish entity, Presbia Ireland, Limited, operating primarily in South Korea, Australia, the Netherlands, Ireland and Canada. Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange losses were $6,000 and $19,000 for the years ended December 31, 2015, and 2014, respectively. Concentrations of Credit Risk Cash is generally deposited in demand deposit accounts that, from time to time, may exceed insurable limits. The Company has not experienced any losses from its deposits of cash. Fair Value of Financial Instruments The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. Amounts payable to related parties, including the payable due to the Parent, which has no fixed maturity or expiration date, do not have readily determinable fair values. Cash The Company considers highly liquid investments with original maturities less than 90 days to be cash equivalents. As of December 31, 2015 and 2014, the Company had no such short-term investment instruments and maintained its cash in bank demand deposit accounts. Inventory The Company accounts for inventory at the lower of market or cost. Inventory is stated at weighted average cost, which is determined by applying the current average cost to the ending inventory. Inventory consists of lenses and lens inserters and other accessories used by physicians in the surgical process associated with the lenses. The Company maintains serialized records of all lenses, including the five-year expiration date of each lens, after which the lens cannot be sold. The Company considers the expiration dates of lenses, in addition to comparing the carrying amount of inventory to expected demand, and will write-down inventory for amounts determined to be excess or obsolete. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three to ten years. Leasehold improvements are amortized over the lesser of the useful life of the asset or the remaining term of the lease. Repairs and maintenance of property and equipment are expensed as incurred. Upon retirement or sale, the original cost and accumulated depreciation are removed and any gain or loss is recognized in the consolidated statements of operations and comprehensive loss. Impairment of Long-Lived Assets The Company reviews the recoverability of long-lived and finite-lived intangible assets when circumstances indicate that the carrying amount of assets might not be recoverable. This evaluation is based on various analyses, including undiscounted cash flow projections. In the event undiscounted cash flow projections indicate impairment, the Company would record an impairment based on the fair value of the assets at the date of the impairment. Intangible Assets In 2009, the Parent acquired Visitome, Inc. by issuing capital stock valued at $50,000. The Parent assigned a fair value of $50,000 to the net assets acquired which included a finite-lived intangible asset of $24,000, property and equipment of $11,000 and goodwill of $15,000. The intangible asset was fully amortized through August 2014 on a straight-line basis over its estimated useful life of five years. The Company amortized $0 and $3,200 in 2015 and 2014, respectively. Costs incurred to develop software for the Company’s website are capitalized and amortized over the estimated useful life of the software and are included in intangible assets. Costs related to design or maintenance of website development is expensed as incurred. For the years ended December 31, 2015 and 2014, the Company capitalized $0 and $46,000, respectively, associated with website development. Amortization expense of $14,000, and $0 was recorded in 2015 and 2014, respectively. Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the years ended December 31, 2015 and 2014. Revenue Recognition The Company recognizes revenue when there is persuasive evidence that an arrangement exists with the customer, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue is recognized upon shipment and payments are either received in advance, or net 30 days. In the years ended December 31, 2015 and 2014 there were six and four customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2015, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’ revenues are derived from foreign customers. Laser Center Revenues The Company recognized revenues of $109,000, and $153,000 from laser centers during the years ended December 31, 2015 and 2014, respectively. The Company recognizes revenue from these laser centers based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Distributor Revenues During the years ended December 31, 2015 and 2014, approximately $44,000, and $4,000 of revenue were recognized from distributor arrangements. The distributor arrangements include certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. The Company has not had any significant rejected shipments or warranty claims. In 2013 the Company changed its commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives. Clinical Trials In February 2015, the Company received approval from the FDA to commence enrollment of the second stage of its U.S. staged pivotal clinical trial of its Microlens involving the implantation of presbyopic patients. Enrollment for the second stage was completed in September 2015. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies, third party costs to monitor the investigational sites and perform data collection activities and surgeon and patient fees in connection with the surgical procedures and follow-up visits. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense. Stock-Based Compensation The compensation cost of stock-based awards granted to employees is measured at grant date, based on the estimated fair value of the award. The Company estimates the fair value of stock options using a Black-Scholes option pricing model. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Stock-based compensation costs are expensed on a straight-line basis (net of estimated forfeitures) over the service period. The fair value of awards granted to non-employees is remeasured each period until the related service is complete or there exists a significant disincentive not to perform the required services. Stock-based compensation costs are reflected in the accompanying statements of operations and comprehensive loss based upon the underlying employees’ roles within the Company. Deferred Offering Costs Generally, costs incurred such as legal, accounting and other professional fees including printing costs in the course of preparing for an IPO are deferred on the balance sheet as deferred offering costs, which are eventually reclassified when the IPO is concluded as a reduction of the proceeds of the IPO as part of additional paid in capital. In the event the IPO is delayed or postponed for a period longer than 90 days or the Company determines that it no longer expects to conclude the IPO for any reason, the deferred offering costs are expensed as general and administrative expense on the consolidated statements of operations and comprehensive loss in the period in which the delay occurs or the period in which management determines that the public offering is postponed, delayed indefinitely or cancelled. In the second and third quarters of 2014, approximately $3.4 million of such IPO costs was expensed as general and administrative expense due to a postponement of the Company’s IPO that exceeded 90 days. During September 2014, the Company resumed preparations for the IPO and incurred approximately $0.8 million between the resumption date and December 31, 2014, and recognized this amount as part of other assets on the balance sheet as of December 31, 2014. Income Taxes For the years ended December 31, 2015 and 2014, the Company was generally not subject to income taxes, as income or loss was either passed-through and included in the income tax returns of the Company’s shareholders or otherwise not subject to tax under local statute or rulings. As described in Note 1, the Parent completed a restructuring on October 21, 2013. As a result, some of the entities are no longer pass-through entities or were restructured as taxable entities. Provisions for federal, foreign, state, and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are recorded for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. Advertising Costs The Company incurs direct response advertising expense outside the United States in order to create awareness of the Company’s Microlens solution to presbyopia. The Company’s policy with respect to direct response advertising is to defer costs related to media and setup costs and amortize those costs to the statement of operations in the period in which the related revenue is recognized. Due to the early stages of market development and the uncertainty around the impact of advertising campaigns to-date, the Company expensed approximately $79,000, and $244,000 as part of sales and marketing expense in the consolidated statements of operations for the years ended December 31, 2015 and 2014, respectively. Risks and Uncertainties The Company’s product requires the approval of the FDA and regulatory agencies in the countries where the Company operates or expects to establish operations in the future. There is no assurance that the Company’s Recently Issued Accounting Standards In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory In January 2015, the FASB issued ASU No. 2015-01, Income Statement-Extraordinary and Unusual Items (Topic 225). The FASB issued ASU 2014-15 on August 27, 2014, providing guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. We are currently evaluating the impact that the adoption of this guidance will have on our consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date

Inventory

Inventory	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory	(3) Inventory The Company maintains a serial number tracking system that measures shelf life such that no lens that has aged beyond four years shall be delivered to a customer. During the years ended December 31, 2015 and 2014, inventory write-downs reflecting excess quantities on hand were recognized in the amount of $169,000 and $61,000, respectively, based on the age of the lens inventory, inserters, accessories and the refractive mix of the inventory. Finished goods inventory consists of the following (in thousands): December 31, 2015 2014 Lenses $ 294 $ 371 Accessories 136 7 Inventory $ 430 $ 378

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Property and Equipment	(4) Property and Equipment Property and equipment consists of the following (in thousands): December 31, 2015 2014 Office equipment and computers $ 74 $ 51 Leasehold improvements 142 132 Production equipment and facilities 752 682 Software 58 7 Construction In Process 1 — Furniture and vehicles 167 155 1,194 1,027 Less: accumulated depreciation (419 ) (280 ) Property and equipment, net $ 775 $ 747 Depreciation and amortization expense related to property and equipment for the years ended December 31, 2015 and 2014 was $159,000 and $135,000, respectively.

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2015
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Other Assets	(5) Other Assets Other assets consists of the following (in thousands): December 31, 2015 2014 Prepaid rent and other assets $ 63 $ 47 Deferred costs related to the initial public offering — 839 $ 63 $ 886

Other Current Liabilities

Other Current Liabilities	12 Months Ended
	Dec. 31, 2015
Other Liabilities Current [Abstract]
Other Current Liabilities	(6) Other Current Liabilities Other current liabilities consists of the following as of the dates set forth below (in thousands): December 31, 2015 2014 Costs related to the initial public offering $ — $ 327 Accrued professional fees 33 20 Accrued payroll related and bonuses 307 114 Accrued utilities and outside services 90 137 Accrued other expense 61 56 Income Tax Payable 44 28 Deferred Tax Liability 34 9 $ 569 $ 691

Loss per Share

Loss per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Loss per Share	(7) Loss per Share Basic net loss per ordinary share is calculated by dividing net loss allocated to ordinary shareholders by the weighted average number of ordinary shares outstanding during the reporting period. Diluted net loss allocated to ordinary shareholders per share is calculated based on the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding during the period. Dilutive potential ordinary shares consist of the shares issuable upon the exercise of options and upon the vesting of restricted shares under the treasury stock method. In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded. Basic and diluted net loss per share were calculated as follows (in thousands, except share and per share data): December 31, 2015 2014 Net Loss $ (18,161 ) $ (15,664 ) Net income allocated to participating securities — — Net loss allocated to common shareholders $ (18,161 ) $ (15,664 ) Weighted average shares outstanding - basic and diluted 12,945,968 9,166,667 Basic and diluted net loss per share $ (1.40 ) $ (1.71 ) The aggregate 9,166,667 ordinary shares of the Company prior to the initial public offering have been reflected as issued and outstanding at December 31, 2014 for purposes of computation of basic and diluted loss per share. Antidilutive securities, which consist of options and restricted shares that are not included in the diluted net loss per share calculation, consisted of an aggregate of 1,044,743 and zero weighted average shares for the fiscal years ended December 31, 2015 and 2014, respectively.

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Shareholders' Equity (Deficit)	(8) Shareholders’ Equity (Deficit) Deferred Ordinary Shares Capital related to Presbia PLC at December 31, 2014 consisted of ordinary shares (“Euro Ordinary Shares”) of $54,000, €1.00 par value, 40,000 authorized and issued with effective date of formation of February 6, 2014 (paid-in on January 10, 2014 with $1.35: €1.00). On January 14, 2015 the Company amended its memorandum and articles of association, resulting in the re-designation of the 40,000 Euro Ordinary Shares as deferred ordinary shares (“Deferred Ordinary Shares”). In August 2015, the Company cancelled 6 Deferred Ordinary Shares pursuant to the distribution of assets held by Presbia Holdings to its ordinary shareholders. The rights and preferences of the Deferred Ordinary Shares are as follows: (i) subject to the right of the Company to set record dates for the purposes of determining the identity of shareholders entitled to notice of and/or to vote at a general meeting, the right to attend and speak at any general meeting of the Company and to exercise one vote per Euro Ordinary Share held at any general meeting of the Company; (ii) the right to participate pro rata in all dividends declared by the Company; and (iii) the right, in the event of the Company’s winding up, to participate pro rata in the total assets of the Company. The rights attaching to the Euro Ordinary Shares may be subject to the terms of issue of any series or class of preferred shares allotted by the Company’s board of directors from time to time in accordance with articles of association.

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Disclosure Of Compensation Related Costs Share Based Payments	(9) Stock Options Stock-Based Compensation Plans On January 14, 2015, the Company approved a compensation incentive plan (the “Presbia Incentive Plan”). The Presbia Incentive Plan permits the Company to grant awards of options, restricted shares, share appreciation rights, restricted stock units, performance shares, performance share units, dividend equivalent rights in respect of awards and other share-based and cash-based awards, including long-term and annual cash incentive awards. A total of 1,800,000 ordinary shares are authorized for issuance under the Presbia Incentive Plan of which approximately 693,000 were available on December 31, 2015 for future grants and awards. The exercise price of each grant shall be determined by the Board of Directors (or a committee thereof) at the grant date in accordance with the terms of the Presbia Incentive Plan, which generally vests awards 20% annually over a five-year period and expire no later than 10 year from the grant date. The Presbia Incentive Plan terminates on January 14, 2025, unless terminated earlier by the board of directors. Awards under the Presbia Incentive Plan may be granted to employees, directors, consultants and other persons who perform services for the Company or a subsidiary of the Company. As of December 31, 2014, the Company did not have any active or inactive stock-based compensation plans; however, during the year ended December 31, 2010 and in October 2013, the Parent granted options to purchase its ordinary shares and granted awards of restricted ordinary shares, to both employees and non-employees of the Company and stock-based compensation related to such awards has been recognized as expense in the accompanying financial statements as described further below. Equity Issued by Presbia PLC in 2015 Options The following table sets forth the Company’s option activity for the fiscal year ended December 31, 2015: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2015 and 2014 - $ - — Granted 1,110,500 $ 9.71 — Exercised - $ - — Forfeited/cancelled (25,917 ) $ 8.98 — Balance, December 31, 2015 1,084,583 $ 9.73 — Vested and expected to vest, December 31, 2015 1,001,134 $ 9.73 — Exercisable, December 31, 2015 90,000 $ 10.00 — Employee Options The Company utilizes the Black-Scholes valuation model for estimating the fair value of share-based compensation representing 1,032,500 options granted to employees and non-employee directors during 2015 with the following assumptions: Year Ended December 31, 2015 Stock price per share $4.39 - $10.00 Term 5.5 - 6.5 Yrs. Volatility 69.8% - 84.6% Dividends — Risk-free rate 1.3% - 2.0% The stock price per share is the range of closing stock prices for the Company’s ordinary shares associated with the award grant dates. The term is the expected term of the option utilizing the simplified method because of the Company’s limited history of option exercise activity and its options meeting the criteria of the “plain vanilla” options as defined by the Securities and Exchange Commission. Also, due to its limited stock price volatility history, the Company uses a peer group average under ASC 718 consistent with the expected term of the option in effect at the time of the grant. The risk-free rate is based on the U.S. Treasury yield consistent with the expected term of the option at the time of the grant. The weighted average grant date fair value of the employee options granted during 2015 was $6.74 per share. For those options granted to employees, stock-based compensation expense is based upon the fair value of the option as of the grant-date and attributed to future reporting periods on a straight-line basis over the vesting period, or the requisite service period. A 5% forfeiture rate assumption was applied, which reduces the amount of expense recognized each period anticipating that a portion of all options will, more likely than not, be cancelled prior to the dates of its vesting periods. The forfeiture rate is subject to review and may be adjusted based upon experience. Non-Employee Options The Company utilizes the Black-Scholes valuation model for estimating the fair value of share-based compensation representing 78,000 options granted to non-employees and consultants during 2015 with the following assumptions: Year Ended December 31, 2015 Stock price per share $ 5.26 Expected term 9.2 - 9.9 Yrs. Volatility 75.8% - 78.8% Dividends — Risk-free rate 2.3% In contrast to the determination of the value of options granted to employees and non-employee directors, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair value for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared. Because the performance criteria of these grants is based solely upon a requisite service period, and are subject to forfeiture if the service conditions are not met, stock-based compensation expense is determined by a straight-line attribution of the remeasured expense (mark-to-market) over the requisite service period subject to a forfeiture rate of 5%. Restricted Shares During 2015, the Company granted 29,559 restricted ordinary shares to newly-appointed independent board members effective with their appointment date joining the board. These grants vest in five equal, annual installments commencing one-year after the date of the grant. The weighted average grant date fair value was determined by referring to the closing price of the Company’s ordinary shares on the dates of the grants. During 2015, one director resigned from the board and joined the Company’s Medical Advisory Board and, as such, the board fully vested 1,854 shares on an accelerated basis and 7,416 were cancelled. As of December 31, 2015, there were 20,289 unvested restricted shares with a weighted average grant date fair value of $7.89 per share. During 2015, The Company recorded compensation expense related to restricted shares of $38,400. The following table sets forth the Company’s restricted share activity for the fiscal year ended December 31, 2015: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2014 - Granted 29,559 $ 8.12 Vested (1,854 ) $ 8.63 Forfeited/cancelled (7,416 ) $ 8.63 Unvested, December 31, 2015 20,289 $ 7.89 Vested and expected to vest, December 31, 2015 19,935 $ 7.83 Vested, December 31, 2015 1,854 $ 8.63 Stock-Based Compensation Expense During 2015, the Company recognized stock-based compensation expense for equity awards as follows (in thousands): Year Ended December 31, 2015 Research and development $ 223 General and administrative 1,762 Sales and marketing 165 $ 2,150 Unrecognized Share-Based Compensation As of December 31, 2015, there was $4.6 million of unrecognized option expense related to employees and non-employees which is expected to be recognized by the Company over the weighted average remaining vesting period of 3.7 years. For restricted share expense, unrecognized compensation expense is estimated to be $124,000 and to be recognized over the weighted average vesting period of 4.4 years. Equity Issued by Presbia Holdings Non-Employee Stock-Based Compensation Stock-based compensation expense related to stock options granted to non-employees is recognized as the stock options are earned. It was concluded that the fair value of the stock options is more reliably measurable than the fair value of the services received. The fair value of non-employee stock options are calculated at each reporting date, using the Black-Scholes option-pricing model, until the award vests or there is a substantial disincentive for the non-employee not to perform the required services. For a discussion of the valuation methods and assumptions utilized for the remeasurement of non-employee awards during the years ended December 31, and 2014, see “Valuation of Parent’s Ordinary Shares” below. The following table sets forth the required inputs to determine the fair values for the non-employee Parent-related stock options: Year Ended December 31, 2015 2014 Stock price per share $ — $ 0.40 Term — 8.8 yrs. Volatility — 77 % Dividends — — Risk-free rate — 2.1 % Employee Stock Awards During 2010 and in October 2013, the Parent granted stock options for shares of its common stock and restricted shares to employees, consultants, medical advisory members and board members in exchange for future services. Since the stock-based compensation expenses that were recognized by the Parent were incurred to benefit the Company, these expenses have been allocated to the Company. The options expire 10 years from the date of the grant and have vesting periods of five years with 20% vesting in each of the five years. Compensation cost for employee stock-based awards is based on the estimated grant date fair value and is recognized over the service period of the applicable award on a straight-line basis. At the time of the option grant date, the Black-Scholes option pricing model was used to determine the fair value of employee stock options. To apply the Black-Scholes option pricing model, the grant-date fair value of the underlying common stock price or value of the shares is adjusted based on the assumptions regarding the volatility of the common stock prices or share values, the expected term of the option and the risk-free interest rate corresponding to a time period equivalent to the expected term of the option. Volatility was based on the stock volatility of comparable public companies within the same industry. Restricted Shares In October 2013, the Parent granted 1,000,000 restricted ordinary shares to its then president, Zohar Loshitzer and 250,000 each to two board members at a fair value of $0.30 per restricted share, and in the case of the two board members, the vesting period was 20% per year over a five year period. With respect to the 1,000,000 restricted share award to Mr. Loshitzer, the shares would vest over (i) the earlier of a three year vesting period in equal annual installments beginning one year following the date of grant or (ii) the date at the end of any lock-up period as determined by the then contemplated initial public offering. Furthermore, in the case of president, the vesting of the shares was guaranteed regardless of Mr. Loshitzer’s future employment status with the Parent, or with any of its subsidiaries, unless such employment was terminated for cause. Accordingly, with respect to the Mr. Loshitzer’s grant, stock-based compensation expense in 2013 was fully recorded for $300,000. At December 31, 2014, the aggregate unvested restricted ordinary shares for the two board members was 400,000. In May 2015, the Parent accelerated the future vesting dates of all options and restricted shares in anticipation of the distribution of its assets to its ordinary shareholders, and, accordingly, the remaining unvested 400,000 restricted shares became fully vested. Incremental stock-based compensation expense of approximately $104,000 was recognized in the second quarter of fiscal 2015 based upon the 400,000 shares and a fair value of the Parent’s ordinary shares of $0.26 as of the date of modification. No incremental expense for the unvested shares held by the president was recorded. Stock-Based Compensation Expense-Presbia Holdings The employee, non-employee and restricted stock stock-based compensation expense was allocated to the Company from its Parent in the accompanying statements of operations and comprehensive loss for all the periods presented as follows (in thousands): Year Ended December 31, 2015 2014 Research and development $ 28 $ 213 General and administrative 117 81 Sales and marketing 11 19 $ 156 $ 313 The following table sets forth the Parent’s stock option activity for the year ended December 31, 2015: Number of Parent's Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2015 4,835,000 $ 0.11 Granted — $ — Exercised (3,860,000 ) $ 0.08 $ 656 Forfeited/cancelled (975,000 ) $ 0.24 Balance, December 31, 2015 - $ - Intrinsic value is measured using the estimated fair value at the date of grant, or as of December 31 (for outstanding options), less the applicable exercise price. In May and June 2015, all vested and unvested outstanding stock options issued by the Parent were deemed to be fully vested by May 15, 2015 and were subject to expiration, unless exercised by the option holder, by June 15, 2015, for the purpose of distributing the 9,666,667 ordinary shares of Presbia PLC acquired by Presbia Holdings in connection with the 2014 and 2015 Reorganizations and the initial public offering to its ordinary shareholders. On August 3, 2015, the distribution of such shares was completed to its shareholders and Presbia Holdings was dissolved in November 2015. As a result of the acceleration of the vesting dates of these options, incremental stock-based compensation expense was recognized in the amount of approximately $21,000. Unrecognized Stock-Based Compensation Expense-Presbia Holdings As of December 31, 2015, all outstanding stock options and restricted share issued by Presbia Holdings were either exercised and exchanged for shares in Presbia PLC or were expired. Valuation of the Parent’s Ordinary Shares Valuation at December 31, 2015. No valuation of the Parent’s Ordinary Shares was required at December 31, 2015 because the entity was dissolved in November 2015. Valuation at December 31, 2014. The valuation method at December 31, 2014 utilized probability—weighted income and market approaches, in which it assigned an 10% weight to the outcome of the income approach of $1.06 per share and 90% weight to the outcome of the market approach of $0.33 per share to reach a concluded value of $0.40 per share of the ordinary shares of the Parent. The income approach considers future cash flows on a discounted basis (DCF) as one indicator of current value while the market approach considers recent transactions in recent initial public offerings of similar equities including the Company’s anticipated IPO such as for those enterprises in early stages of development, in the biopharmaceutical or medical device industries. The income approach consisted of a base case scenario, which was assigned a 70% probability of success, in which the U.S. FDA clinical trials are concluded in 2017 and revenues commenced in the U.S. in March 2018. The income approach also assigned additional probabilities of 25% and 5% to a delayed case where entry into the U.S. market is delayed by one year to March 2019 and a pessimistic case where FDA approval is not achieved and there is no entry into the U.S. market, respectively. In each scenario, the DCF was discounted by applying a 27.5% discount rate to free cash flows generated in each of a ten-year projection period and a terminal value that represents future cash flows past 2023, the last year in the ten year projection. The weighted-average enterprise value was further discounted by 22% to account for the lack of marketability of the Parent’s ordinary shares to arrive at a concluded value of $0.40 per share. The discount rate of 27.5% applied in the DCF model is based on the Company’s stage of development. The lack of marketability discount of 22% was determined by applying a protective put option analysis reflecting the expected timing of a liquidity event of the Parent’s ordinary shares. The market approach considers recent initial public offerings in ophthalmology and general biotech markets. The initial public offering analysis consisted of inputs provided by the Company’s lead underwriter which considered a range of pre-IPO equity valuation ranging from $90 million to $140 million. This method provides a range of equity values as of an initial public offering date. The range of enterprise values, when attributed to the ordinary shares of the Parent, indicated an average of $0.42 per share. The same lack of marketability discount of 22% was applied to indicate a value per ordinary share of $0.33.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	(10) Related Party Transactions The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets (in thousands): Year Ended December 31, 2015 2014 Payable to related parties-current: Management services provided by related parties $ 55 $ 12 Total $ 55 $ 12 Payable due to the Parent-noncurrent: Principal amounts due to the Parent $ — $ 417 Accrued interest due to the Parent $ — $ — Total $ — $ 417 Mr. Ressler is a member of the Company’s Board of Directors and had served as the Chairman of the Board of the Parent since the Parent’s formation in 2007 and along with immediate family members had a controlling interest in a partnership that controlled the Parent, prior to its dissolution in November 2015. As of December 31, 2014 net principal amounts due to the Parent amounted to $0.4 million. Prior to November 25, 2014, interest on outstanding balances due to the Parent were accrued at a rate of 15% per annum, compounded daily totaling approximately $2.2 million for the twelve months ended December, 31, 2014. The funding debt had no fixed maturity or expiration date and is classified as a noncurrent liability in the accompanying consolidated balance sheet at December 31, 2014. On November 30, 2014, Presbia Holdings converted all the remaining indebtedness owed to Presbia Holdings by certain subsidiaries of Presbia Ireland, Limited at that time to equity (“2014 Debt Conversion”). In the 2014 Debt Conversion, approximately $23.5 million of outstanding intercompany debt owed to Presbia Holdings was converted to equity of such subsidiaries. During the period from December 1, 2014 to January 14, 2015, covering the period immediately prior to the completion of the initial public offering on February 3, 2015, aggregate funding from the Parent to Presbia PLC totaled approximately $1,558,000, of which $417,000 was classified as payable due to Parent on the consolidated balance sheet as of December 31, 2014. Also on November 30, 2014, the Company’s subsidiaries entered into an Interest Rate Agreement (the “Interest Rate Agreement”) with its Parent. Pursuant to the terms of the agreement, the parties agreed that any future borrowings from the Parent shall accrue at a rate, to be adjusted each calendar month, equal to the then applicable monthly federal rate of interest for short-term loans, as defined in Section 1274 of the Internal Revenue Code of 1986, and such interest should accrue daily on the basis of a 365 day year until such amount is repaid in full or such amount has been contributed to capital by the Parent to the Company’s subsidiaries. The agreement provides that any future borrowings shall have no fixed maturity. In January 2015, we effected the 2015 Debt Conversion described under “Part I, Item I, Business—Corporate History and Information.” In the 2015 Debt Conversion, approximately $1.6 million, representing the balance of outstanding intercompany debt owed to Presbia Holdings by a subsidiary of Presbia Ireland, Limited at that time, was converted to equity of such subsidiary. In addition, in January 2015, Presbia Holdings contributed all of the shares in issue of Presbia Ireland, Limited to Presbia PLC, an Irish incorporated public limited company, in exchange for 9,166,667 ordinary shares of Presbia PLC. Presbia Holdings purchased an aggregate of 500,000 ordinary shares in our initial public offering in February 2015. In May 13, 2015, the board of directors of Presbia Holdings approved the liquidation of Presbia Holdings, which liquidation was subsequently approved by the shareholders of Presbia Holdings on May 13, 2015. In connection with the Liquidation, on August 3, 2015, Presbia Holdings distributed, by way of a dividend in specie, the 9,666,667 ordinary shares of the Company that it held as of that date to its equity holders, pro rata based on each such equity holder’s equity ownership in Presbia Holdings. In July 2015, Presbia Holdings incurred and paid bonus payments of approximately $183,000 on behalf of Presbia PLC in connection with the Liquidation. Since 2011, Orchard Capital Corporation (“Orchard”), which is wholly-owned by Mr. Ressler, has provided financial analysis and bookkeeping, accounting, legal, compliance and directorial services to the Company pursuant to a Services Agreement. During the years ended December 31, 2015, and 2014, the Company recognized general and administrative expense of $139,000, and $18,000, respectively, for services invoiced by Orchard. As of December 31, 2015 and 2014, amounts due to Orchard for management and accounting services amounted to $2,000 and $23,000, respectively. Commencing during the second quarter of 2013, the Company has received human resources management services, payroll services, IT support and risk management services from CIM Group, an entity in which Mr. Ressler has a controlling interest. The Company has incurred charges of $185,000 and $152,000 payable to CIM Group for such services for the years ended December 31, 2015 and 2014, respectively. As of December 31, 2015 and 2014, amounts due to CIM Group for human resources, payroll, information technology and legal services amounted to $53,000 and $12,000, respectively.

Operating Segments and Geograph

Operating Segments and Geographic Information	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Operating Segments and Geographic Information	(11) Operating Segments and Geographic Information The Company operates in one operating segment, the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. Revenue originating in the United States is limited to intercompany transactions that do not result in any revenue generating activities to any individual or physician in the United States, and these amounts are eliminated upon consolidation. The operating losses in the United States result primarily from research and development and general and administrative costs while the operating losses in the foreign operations result primarily from sales and marketing costs and an allocation of general and administrative costs to foreign operations. Revenues from external customers to individual countries are allocated based on the location of the customer. For the periods presented, there was no more than one customer in each individual country. The following table sets forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area (in thousands): Year Ended December 31, Revenues 2015 2014 Australia $ 2 $ - Brazil - - Canada 9 4 Ireland 67 149 Italy - 4 Japan - 4 South Korea 44 - The Netherlands 29 - UK 2 - Total $ 153 $ 161 Year Ended December 31, Long-lived Assets 2015 2014 U.S. 736 716 Foreign 39 31 Total $ 775 $ 747 In the years ended December 31, 2015 and 2014 there were six and four customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2015, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’ revenues are derived from foreign customers. With respect to suppliers for the microlens, the Company has a five-year supplier agreement that will expire in January 2017 with a lens manufacturer in Israel from which the Company receives 100% of its lens supply for use in commercial activities outside the United States. The Company also has its own manufacturing facility in Irvine, California that we believe can be scaled to meet excessive lens demand or a disruption of supply sourced from outside the United States.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(12) Commitments and Contingencies Facility Leases In May 2012, the Company entered into a five-year non-cancelable lease for office and manufacturing space in Irvine, California that expires in May 2017, a 26-month sublease of office space in the same California location that commenced in June 2014 and will expire in July 2016, a one-year lease (which is now month to month) in Dublin, Ireland that commenced on December 1, 2013, and a 30-month lease in Amsterdam, the Netherlands that commenced on January 1, 2016. Rent expense for the years ended December 31, 2015 and 2014 was $209,000 and $234,000, respectively. The following table shows the annual base rental cost over the term of the leases (in thousands). Years Ended December 31, Obligations Under Facility Leases 2016 178 2017 63 2018 7 2019 — 2020 — 2021 and Thereafter — Total $ 248 Contingencies From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial operations.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	(13) Income Taxes The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2015 2014 Current provision: Federal $ — $ — State 3 2 Foreign 16 8 Total current $ 19 $ 10 Deferred provision Federal (306 ) (90 ) State — — Foreign (1,574 ) (886 ) Total deferred (1,880 ) (976 ) Valuation allowance 1,880 976 Total deferred — — Total income tax provision $ 19 $ 10 A reconciliation of the federal statutory rate to the effective rate is as follows: Year Ended December 31, 2015 2014 Expected income tax benefit at federal statutory rate 35 % 35 % State tax provision, net of federal benefit 0 % 0 % Foreign rate differential (25 %) (24 %) Pass-through entities 0 % 0 % Change in valuation allowance (10 %) (6 %) Nondeductible expenses 0 % (5 %) Other 0 % 0 % Income tax provision (0.0 %) (0.1 %) The components of the Company’s deferred tax assets are summarized as follows (in thousands): Year Ended 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 3,072 $ 1,201 Accrued expenses 27 44 Stock based compensation 241 186 Deferred tax assets 3,340 1,431 Valuation allowance (3,247 ) (1,366 ) Net deferred tax assets 93 65 Deferred tax liabilities: Depreciation (93 ) (65 ) Total deferred tax liabilities (93 ) (65 ) Net deferred tax asset $ — $ — The valuation allowance has been established to offset the Company’s net deferred tax assets, as realization of such assets is not considered to be more likely than not due to the Company’s history of losses and uncertainties regarding the Company’s ability to generate future taxable income sufficient to realize the benefit of these deferred tax assets. The Company has U.S. Federal net operating loss (“NOL”) carryforwards of approximately $1,618,000 and $729,000 for December 31, 2015 and 2014, respectively, subject to potential limitations pursuant to Internal Revenue Code section 382 as discussed below. The federal NOL carryforwards will begin to expire in 2033, unless previously utilized. The Company has NOL carryforwards in Ireland of $20.2 million and $7.6 million for December 31, 2015 and 2014, respectively, which can be carried forward indefinitely. Pursuant to Section 382 of the Internal Revenue Code (the “Code”), annual use of the Company’s NOL carryforwards may be limited in the event a cumulative change in ownership of 50% of certain shareholders occurs within a three-year period. An ownership change may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income and tax. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain shareholders. Presbia Coopratief U.A. is a Dutch Company that has received an advance ruling with the Tax and Customs Administration that is in effect from January 1, 2012 to December 31, 2015. As of December 31, 2015 and 2014, the Company did not have any unrecognized tax benefits. The Company does not anticipate a significant increase in the unrecognized tax benefits over the next 12 months. The Company’s policy is to recognize interest expense and penalties related to income tax matters as a component of the income tax provision. As of December 31, 2015 and 2014, the Company did not have any tax related accrued interest and penalties on its balance sheet or on its statement of operations. Due to net operating loss carryovers, the U.S. federal and state returns are open to examination by the Internal Revenue Service and state jurisdictions for years 2008 through 2015. The foreign income tax returns are open to examination for the years 2012 through 2015. The Company recognizes tax benefits associated with the exercise of stock options directly to stockholders’ equity only when realized. A windfall tax benefit occurs when the actual tax benefit realized upon an employee’s disposition of a share based award exceeds the deferred tax asset, if any, associated with the award. At December 31, 2015 and 2014, deferred tax assets did not include $39,000 of excess tax benefits from stock based compensation.

Quarterly Financial Data (unaud

Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (unaudited)	(14) Quarterly Financial Data (unaudited) The following tables present the unaudited financial data for each of the interim periods in 2015 and 2014: Quarter Ended (unaudited) 3/31/2015 6/30/2015 9/30/2015 12/31/2015 Revenues $ 73 $ 42 $ 10 $ 28 Cost of goods sold 47 14 34 68 Operating expenses: Research and development (a) 1,776 2,502 2,333 1,324 Sales and marketing 519 834 760 593 General and administrative 2,319 2,007 1,762 1,391 Operating loss (4,588 ) (5,315 ) (4,879 ) (3,348 ) Interest expense — — — - Other expense — — 12 — Loss before income tax provision (4,588 ) (5,315 ) (4,891 ) (3,348 ) Income tax provision 5 4 9 1 Net loss $ (4,593 ) $ (5,319 ) $ (4,900 ) $ (3,349 ) Net loss per share-basic and diluted $ (0.39 ) $ (0.40 ) $ (0.37 ) $ (0.25 ) Weighted average shares basic and diluted 11,759,260 13,333,334 13,334,503 13,335,188 Quarter Ended (unaudited) 3/31/2014 6/30/2014 9/30/2014 12/31/2014 Revenues $ 26 $ 61 $ 38 $ 36 Cost of goods sold 6 33 6 16 Operating expenses: Research and development (a) 732 1,675 1,016 820 Sales and marketing 249 394 463 546 General and administrative (b) 1,376 4,272 881 1,048 Operating loss (2,337 ) (6,313 ) (2,328 ) (2,394 ) Interest expense 433 584 719 552 Other expense — (6 ) — — Loss before income tax provision (2,770 ) (6,891 ) (3,047 ) (2,946 ) Income tax provision 2 3 5 — Net loss $ (2,772 ) $ (6,894 ) $ (3,052 ) $ (2,946 ) Net loss per share-basic and diluted $ (0.30 ) $ (0.75 ) $ (0.33 ) $ (0.32 ) Weighted average shares basic and diluted 9,166,667 9,166,667 9,166,667 9,166,667 (a) Includes costs related to U.S clinical trials. (b) Includes $3.4 million write-off of deferred offering costs in the second quarter of 2014.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Event	(15) Subsequent Events Effective January 19, 2016, Dr. Gerald Farrell joined the Presbia PLC board of directors and will serve as an independent member of the Audit Committee. In connection with joining the board of directors, Dr. Farrell was awarded 15,968 restricted stock (RSA’s) at a January 19, 2016 closing price of $5.01.

Schedule II - Consolidated Valu

Schedule II - Consolidated Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation And Qualifying Accounts [Abstract]
Consolidated Valuation and Qualifying Accounts	Schedule II – Consolidated Valuation and Qualifying Accounts Balance at Beginning of Period Additional Allowance Adjustments Balance at End of Period Deferred Income Tax Asset Valuation Allowance Year ended December 31, 2014 262 1,045 68 1,375

Basis of Presentation (Policies

Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Liquidity	Liquidity The Company has incurred significant operating losses since inception and has relied on funding from its Parent to fund our operations prior to its initial public offering concluded on February 3, 2015. At December 31, 2015, the Company has an accumulated deficit of $55.5 million. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval and commercialization of its product and on the achievement of sufficient revenues to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Management expects that existing cash as of December 31, 2015 of $21.7 million will be sufficient to fund the Company’s operations through December 31, 2016.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management makes estimates and assumptions that are included in the consolidated financial statements and accompanying notes. The actual results may differ from those estimates.
Segment Information	Segment Information In accordance with Accounting Standard Codification (“ASC”) 280-10-50, Segment Reporting, operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Since 2013, the Company has viewed and managed its operations and business as one segment through its wholly-owned Dutch subsidiary, Presbia Cooperatief U.A. and its wholly-owned Irish entity, Presbia Ireland, Limited, operating primarily in South Korea, Australia, the Netherlands, Ireland and Canada.
Foreign Currency	Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange losses were $6,000 and $19,000 for the years ended December 31, 2015, and 2014, respectively.
Concentrations of Credit Risks	Concentrations of Credit Risk Cash is generally deposited in demand deposit accounts that, from time to time, may exceed insurable limits. The Company has not experienced any losses from its deposits of cash.
Fair Value Of Financial Instruments Policy	Fair Value of Financial Instruments The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. Amounts payable to related parties, including the payable due to the Parent, which has no fixed maturity or expiration date, do not have readily determinable fair values.
Cash	Cash The Company considers highly liquid investments with original maturities less than 90 days to be cash equivalents. As of December 31, 2015 and 2014, the Company had no such short-term investment instruments and maintained its cash in bank demand deposit accounts.
Inventory	Inventory The Company accounts for inventory at the lower of market or cost. Inventory is stated at weighted average cost, which is determined by applying the current average cost to the ending inventory. Inventory consists of lenses and lens inserters and other accessories used by physicians in the surgical process associated with the lenses. The Company maintains serialized records of all lenses, including the five-year expiration date of each lens, after which the lens cannot be sold. The Company considers the expiration dates of lenses, in addition to comparing the carrying amount of inventory to expected demand, and will write-down inventory for amounts determined to be excess or obsolete.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three to ten years. Leasehold improvements are amortized over the lesser of the useful life of the asset or the remaining term of the lease. Repairs and maintenance of property and equipment are expensed as incurred. Upon retirement or sale, the original cost and accumulated depreciation are removed and any gain or loss is recognized in the consolidated statements of operations and comprehensive loss.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews the recoverability of long-lived and finite-lived intangible assets when circumstances indicate that the carrying amount of assets might not be recoverable. This evaluation is based on various analyses, including undiscounted cash flow projections. In the event undiscounted cash flow projections indicate impairment, the Company would record an impairment based on the fair value of the assets at the date of the impairment.
Intangible Assets	Intangible Assets In 2009, the Parent acquired Visitome, Inc. by issuing capital stock valued at $50,000. The Parent assigned a fair value of $50,000 to the net assets acquired which included a finite-lived intangible asset of $24,000, property and equipment of $11,000 and goodwill of $15,000. The intangible asset was fully amortized through August 2014 on a straight-line basis over its estimated useful life of five years. The Company amortized $0 and $3,200 in 2015 and 2014, respectively. Costs incurred to develop software for the Company’s website are capitalized and amortized over the estimated useful life of the software and are included in intangible assets. Costs related to design or maintenance of website development is expensed as incurred. For the years ended December 31, 2015 and 2014, the Company capitalized $0 and $46,000, respectively, associated with website development. Amortization expense of $14,000, and $0 was recorded in 2015 and 2014, respectively.
Comprehensive Loss	Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the years ended December 31, 2015 and 2014.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when there is persuasive evidence that an arrangement exists with the customer, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue is recognized upon shipment and payments are either received in advance, or net 30 days. In the years ended December 31, 2015 and 2014 there were six and four customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2015, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’ revenues are derived from foreign customers. Laser Center Revenues The Company recognized revenues of $109,000, and $153,000 from laser centers during the years ended December 31, 2015 and 2014, respectively. The Company recognizes revenue from these laser centers based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Distributor Revenues During the years ended December 31, 2015 and 2014, approximately $44,000, and $4,000 of revenue were recognized from distributor arrangements. The distributor arrangements include certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. The Company has not had any significant rejected shipments or warranty claims. In 2013 the Company changed its commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives.
Clinical Trials	Clinical Trials In February 2015, the Company received approval from the FDA to commence enrollment of the second stage of its U.S. staged pivotal clinical trial of its Microlens involving the implantation of presbyopic patients. Enrollment for the second stage was completed in September 2015. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies, third party costs to monitor the investigational sites and perform data collection activities and surgeon and patient fees in connection with the surgical procedures and follow-up visits. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense.
Stock-Based Compensation	Stock-Based Compensation The compensation cost of stock-based awards granted to employees is measured at grant date, based on the estimated fair value of the award. The Company estimates the fair value of stock options using a Black-Scholes option pricing model. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Stock-based compensation costs are expensed on a straight-line basis (net of estimated forfeitures) over the service period. The fair value of awards granted to non-employees is remeasured each period until the related service is complete or there exists a significant disincentive not to perform the required services. Stock-based compensation costs are reflected in the accompanying statements of operations and comprehensive loss based upon the underlying employees’ roles within the Company.
Deferred Offering Costs	Deferred Offering Costs Generally, costs incurred such as legal, accounting and other professional fees including printing costs in the course of preparing for an IPO are deferred on the balance sheet as deferred offering costs, which are eventually reclassified when the IPO is concluded as a reduction of the proceeds of the IPO as part of additional paid in capital. In the event the IPO is delayed or postponed for a period longer than 90 days or the Company determines that it no longer expects to conclude the IPO for any reason, the deferred offering costs are expensed as general and administrative expense on the consolidated statements of operations and comprehensive loss in the period in which the delay occurs or the period in which management determines that the public offering is postponed, delayed indefinitely or cancelled. In the second and third quarters of 2014, approximately $3.4 million of such IPO costs was expensed as general and administrative expense due to a postponement of the Company’s IPO that exceeded 90 days. During September 2014, the Company resumed preparations for the IPO and incurred approximately $0.8 million between the resumption date and December 31, 2014, and recognized this amount as part of other assets on the balance sheet as of December 31, 2014.
Income Taxes	Income Taxes For the years ended December 31, 2015 and 2014, the Company was generally not subject to income taxes, as income or loss was either passed-through and included in the income tax returns of the Company’s shareholders or otherwise not subject to tax under local statute or rulings. As described in Note 1, the Parent completed a restructuring on October 21, 2013. As a result, some of the entities are no longer pass-through entities or were restructured as taxable entities. Provisions for federal, foreign, state, and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are recorded for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized.
Advertising Costs	Advertising Costs The Company incurs direct response advertising expense outside the United States in order to create awareness of the Company’s Microlens solution to presbyopia. The Company’s policy with respect to direct response advertising is to defer costs related to media and setup costs and amortize those costs to the statement of operations in the period in which the related revenue is recognized. Due to the early stages of market development and the uncertainty around the impact of advertising campaigns to-date, the Company expensed approximately $79,000, and $244,000 as part of sales and marketing expense in the consolidated statements of operations for the years ended December 31, 2015 and 2014, respectively.
Risks and Uncertainties	Risks and Uncertainties The Company’s product requires the approval of the FDA and regulatory agencies in the countries where the Company operates or expects to establish operations in the future. There is no assurance that the Company’s
Recently Issued Accounting Standards	Recently Issued Accounting Standards In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory In January 2015, the FASB issued ASU No. 2015-01, Income Statement-Extraordinary and Unusual Items (Topic 225). The FASB issued ASU 2014-15 on August 27, 2014, providing guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. We are currently evaluating the impact that the adoption of this guidance will have on our consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Summary of Finished Goods Inventory	Finished goods inventory consists of the following (in thousands): December 31, 2015 2014 Lenses $ 294 $ 371 Accessories 136 7 Inventory $ 430 $ 378

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consists of the following (in thousands): December 31, 2015 2014 Office equipment and computers $ 74 $ 51 Leasehold improvements 142 132 Production equipment and facilities 752 682 Software 58 7 Construction In Process 1 — Furniture and vehicles 167 155 1,194 1,027 Less: accumulated depreciation (419 ) (280 ) Property and equipment, net $ 775 $ 747

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Summary of Other Assets	Other assets consists of the following (in thousands): December 31, 2015 2014 Prepaid rent and other assets $ 63 $ 47 Deferred costs related to the initial public offering — 839 $ 63 $ 886

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Other Liabilities Current [Abstract]
Summary of Other Current Liabilities	Other current liabilities consists of the following as of the dates set forth below (in thousands): December 31, 2015 2014 Costs related to the initial public offering $ — $ 327 Accrued professional fees 33 20 Accrued payroll related and bonuses 307 114 Accrued utilities and outside services 90 137 Accrued other expense 61 56 Income Tax Payable 44 28 Deferred Tax Liability 34 9 $ 569 $ 691

Loss per Share (Tables)

Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of Calculation of Basic and Diluted Loss per Share	Basic and diluted net loss per share were calculated as follows (in thousands, except share and per share data): December 31, 2015 2014 Net Loss $ (18,161 ) $ (15,664 ) Net income allocated to participating securities — — Net loss allocated to common shareholders $ (18,161 ) $ (15,664 ) Weighted average shares outstanding - basic and diluted 12,945,968 9,166,667 Basic and diluted net loss per share $ (1.40 ) $ (1.71 )

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of Option Activity	The following table sets forth the Company’s option activity for the fiscal year ended December 31, 2015: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2015 and 2014 - $ - — Granted 1,110,500 $ 9.71 — Exercised - $ - — Forfeited/cancelled (25,917 ) $ 8.98 — Balance, December 31, 2015 1,084,583 $ 9.73 — Vested and expected to vest, December 31, 2015 1,001,134 $ 9.73 — Exercisable, December 31, 2015 90,000 $ 10.00 —
Schedule of Restricted Shares Activity	The following table sets forth the Company’s restricted share activity for the fiscal year ended December 31, 2015: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2014 - Granted 29,559 $ 8.12 Vested (1,854 ) $ 8.63 Forfeited/cancelled (7,416 ) $ 8.63 Unvested, December 31, 2015 20,289 $ 7.89 Vested and expected to vest, December 31, 2015 19,935 $ 7.83 Vested, December 31, 2015 1,854 $ 8.63
Schedule of Share-based Compensation Expense	During 2015, the Company recognized stock-based compensation expense for equity awards as follows (in thousands): Year Ended December 31, 2015 Research and development $ 223 General and administrative 1,762 Sales and marketing 165 $ 2,150
Presbia Holdings [Member]
Schedule of Option Activity	The following table sets forth the Parent’s stock option activity for the year ended December 31, 2015: Number of Parent's Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2015 4,835,000 $ 0.11 Granted — $ — Exercised (3,860,000 ) $ 0.08 $ 656 Forfeited/cancelled (975,000 ) $ 0.24 Balance, December 31, 2015 - $ -
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	The following table sets forth the required inputs to determine the fair values for the non-employee Parent-related stock options: Year Ended December 31, 2015 2014 Stock price per share $ — $ 0.40 Term — 8.8 yrs. Volatility — 77 % Dividends — — Risk-free rate — 2.1 %
Schedule of Share-based Compensation Expense	The employee, non-employee and restricted stock stock-based compensation expense was allocated to the Company from its Parent in the accompanying statements of operations and comprehensive loss for all the periods presented as follows (in thousands): Year Ended December 31, 2015 2014 Research and development $ 28 $ 213 General and administrative 117 81 Sales and marketing 11 19 $ 156 $ 313
Employee options [Member]
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	The Company utilizes the Black-Scholes valuation model for estimating the fair value of share-based compensation representing 1,032,500 options granted to employees and non-employee directors during 2015 with the following assumptions: Year Ended December 31, 2015 Stock price per share $4.39 - $10.00 Term 5.5 - 6.5 Yrs. Volatility 69.8% - 84.6% Dividends — Risk-free rate 1.3% - 2.0%
Non-employee options [Member]
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	The Company utilizes the Black-Scholes valuation model for estimating the fair value of share-based compensation representing 78,000 options granted to non-employees and consultants during 2015 with the following assumptions: Year Ended December 31, 2015 Stock price per share $ 5.26 Expected term 9.2 - 9.9 Yrs. Volatility 75.8% - 78.8% Dividends — Risk-free rate 2.3%

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Schedule of Amounts Due to Related Parties	The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets (in thousands): Year Ended December 31, 2015 2014 Payable to related parties-current: Management services provided by related parties $ 55 $ 12 Total $ 55 $ 12 Payable due to the Parent-noncurrent: Principal amounts due to the Parent $ — $ 417 Accrued interest due to the Parent $ — $ — Total $ — $ 417

Operating Segments and Geogra31

Operating Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule of Revenues Generated from External Customers and Long-lived Assets by Area	The following table sets forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area (in thousands): Year Ended December 31, Revenues 2015 2014 Australia $ 2 $ - Brazil - - Canada 9 4 Ireland 67 149 Italy - 4 Japan - 4 South Korea 44 - The Netherlands 29 - UK 2 - Total $ 153 $ 161 Year Ended December 31, Long-lived Assets 2015 2014 U.S. 736 716 Foreign 39 31 Total $ 775 $ 747

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Schedule of Annual Base Rental Cost Over the Term of the Leases	The following table shows the annual base rental cost over the term of the leases (in thousands). Years Ended December 31, Obligations Under Facility Leases 2016 178 2017 63 2018 7 2019 — 2020 — 2021 and Thereafter — Total $ 248

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Taxes	The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2015 2014 Current provision: Federal $ — $ — State 3 2 Foreign 16 8 Total current $ 19 $ 10 Deferred provision Federal (306 ) (90 ) State — — Foreign (1,574 ) (886 ) Total deferred (1,880 ) (976 ) Valuation allowance 1,880 976 Total deferred — — Total income tax provision $ 19 $ 10
Schedule of Reconciliation of Federal Statutory Rate to Effective Rate	A reconciliation of the federal statutory rate to the effective rate is as follows: Year Ended December 31, 2015 2014 Expected income tax benefit at federal statutory rate 35 % 35 % State tax provision, net of federal benefit 0 % 0 % Foreign rate differential (25 %) (24 %) Pass-through entities 0 % 0 % Change in valuation allowance (10 %) (6 %) Nondeductible expenses 0 % (5 %) Other 0 % 0 % Income tax provision (0.0 %) (0.1 %)
Components of Deferred Tax Assets	The components of the Company’s deferred tax assets are summarized as follows (in thousands): Year Ended 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 3,072 $ 1,201 Accrued expenses 27 44 Stock based compensation 241 186 Deferred tax assets 3,340 1,431 Valuation allowance (3,247 ) (1,366 ) Net deferred tax assets 93 65 Deferred tax liabilities: Depreciation (93 ) (65 ) Total deferred tax liabilities (93 ) (65 ) Net deferred tax asset $ — $ —

Quarterly Financial Data (una34

Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Summary of Unaudited Financial Data	The following tables present the unaudited financial data for each of the interim periods in 2015 and 2014: Quarter Ended (unaudited) 3/31/2015 6/30/2015 9/30/2015 12/31/2015 Revenues $ 73 $ 42 $ 10 $ 28 Cost of goods sold 47 14 34 68 Operating expenses: Research and development (a) 1,776 2,502 2,333 1,324 Sales and marketing 519 834 760 593 General and administrative 2,319 2,007 1,762 1,391 Operating loss (4,588 ) (5,315 ) (4,879 ) (3,348 ) Interest expense — — — - Other expense — — 12 — Loss before income tax provision (4,588 ) (5,315 ) (4,891 ) (3,348 ) Income tax provision 5 4 9 1 Net loss $ (4,593 ) $ (5,319 ) $ (4,900 ) $ (3,349 ) Net loss per share-basic and diluted $ (0.39 ) $ (0.40 ) $ (0.37 ) $ (0.25 ) Weighted average shares basic and diluted 11,759,260 13,333,334 13,334,503 13,335,188 Quarter Ended (unaudited) 3/31/2014 6/30/2014 9/30/2014 12/31/2014 Revenues $ 26 $ 61 $ 38 $ 36 Cost of goods sold 6 33 6 16 Operating expenses: Research and development (a) 732 1,675 1,016 820 Sales and marketing 249 394 463 546 General and administrative (b) 1,376 4,272 881 1,048 Operating loss (2,337 ) (6,313 ) (2,328 ) (2,394 ) Interest expense 433 584 719 552 Other expense — (6 ) — — Loss before income tax provision (2,770 ) (6,891 ) (3,047 ) (2,946 ) Income tax provision 2 3 5 — Net loss $ (2,772 ) $ (6,894 ) $ (3,052 ) $ (2,946 ) Net loss per share-basic and diluted $ (0.30 ) $ (0.75 ) $ (0.33 ) $ (0.32 ) Weighted average shares basic and diluted 9,166,667 9,166,667 9,166,667 9,166,667 (a) Includes costs related to U.S clinical trials. (b) Includes $3.4 million write-off of deferred offering costs in the second quarter of 2014.

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail)	Aug. 03, 2015shares	Feb. 28, 2015shares	Feb. 03, 2015USD ($)$ / sharesshares	Jan. 14, 2015USD ($)shares	Nov. 30, 2014USD ($)	Feb. 06, 2014USD ($)shares	Feb. 06, 2014EUR (€)shares	Jan. 31, 2015USD ($)	Dec. 31, 2015USD ($)Countryshares	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)
Basis Of Presentation [Line Items]
Date of incorporation									Feb. 6, 2014
Number of ordinary shares, value									$ 36,844,000
Capitalization of amounts due to Parent per 2014 and 2015 Debt Conversions				$ 1,600,000	$ 23,500,000			$ 1,600,000	1,559,000	$ 23,473,000
Other issuance costs									$ 2,431,000	2,151,000
Number of country in which company is authorized to sell, market and perform procedure | Country									40
Accumulated deficit									$ (55,547,000)	(37,386,000)
Cash									$ 21,749,000	$ 138,000	$ 584,000
IPO [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares			4,166,667
Ordinary shares, price per share | $ / shares			$ 10
Gross proceeds from issuance of stock			$ 41,700,000
Underwriting discounts and commission costs			2,900,000
Other issuance costs			2,000,000
Net proceeds from issuance of stock			$ 36,800,000
2015 Capital Contribution [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares				9,166,667						9,166,667
Presbia Holdings [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares	9,666,667					40,000	40,000		9,666,667	9,666,667
Number of ordinary shares, value						$ 54,000	€ 40,000
Percentage of ownership interests						100.00%	100.00%
Presbia Holdings [Member] | IPO [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares		500,000	500,000

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended								12 Months Ended
	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2014USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2015USD ($)Customer	Dec. 31, 2014USD ($)Customer
Subsidiary Sale Of Stock [Line Items]
Short-term investment instruments	$ 0				$ 0				$ 0	$ 0
Expiration period of each lens									5 years
Software capitalized	0				46,000				$ 0	46,000
Amortization expenses of capitalized software									$ 14,000	$ 0
Payments collection period									30 days	30 days
Number of customers | Customer									6	4
Revenues	28,000	$ 10,000	$ 42,000	$ 73,000	36,000	$ 38,000	$ 61,000	$ 26,000	$ 153,000	$ 161,000
Product warranty term									1 year	1 year
Write-off of deferred offering costs							3,400,000			$ 3,369,000
Other assets	63,000				$ 886,000				$ 63,000	886,000
IPO [Member]
Subsidiary Sale Of Stock [Line Items]
Deferred offering cost due to delay									90 days
Write-off of deferred offering costs						$ 3,400,000	$ 3,400,000
Other assets	800,000								$ 800,000
Laser Center Revenues [Member]
Subsidiary Sale Of Stock [Line Items]
Revenues									109,000	153,000
Distributor Revenues [Member]
Subsidiary Sale Of Stock [Line Items]
Revenues									$ 44,000	$ 4,000
Sales [Member] | Customer Concentration [Member]
Subsidiary Sale Of Stock [Line Items]
Concentration risk, percentage									100.00%	100.00%
Visitome, Inc [Member]
Subsidiary Sale Of Stock [Line Items]
Capital stock issued for acquisitions									$ 50,000
Fair value of net assets acquired									50,000
Acquired finite-lived intangible asset									24,000
Property and equipment	11,000								11,000
Goodwill	$ 15,000								$ 15,000
Intangible asset amortization method									Straight-line Method
Estimated useful life of intangible assets									5 years
Amortization of intangible assets									$ 0	$ 3,200
Minimum [Member]
Subsidiary Sale Of Stock [Line Items]
Estimated life of property and equipment									3 years
Customer shipments rejection notifications period									14 days	14 days
Maximum [Member]
Subsidiary Sale Of Stock [Line Items]
Estimated life of property and equipment									10 years
Number of customers | Customer									1
Customer shipments rejection notifications period									45 days	45 days
General and Administrative Expense [Member]
Subsidiary Sale Of Stock [Line Items]
Aggregate foreign exchange losses									$ (6,000)	$ (19,000)
Selling And Marketing Expense [Member]
Subsidiary Sale Of Stock [Line Items]
Advertising costs									$ 79,000	$ 244,000

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory write-downs reflecting excess quantities on hand recognized	$ 169	$ 61

Inventory - Summary of Inventor

Inventory - Summary of Inventory, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Inventory	$ 430	$ 378
Lenses [Member]
Inventory [Line Items]
Inventory	294	371
Accessories [Member]
Inventory [Line Items]
Inventory	$ 136	$ 7

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,194	$ 1,027
Less: accumulated depreciation	(419)	(280)
Property and equipment, net	775	747
Office equipment and computers [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	74	51
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	142	132
Production equipment and facilities [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	752	682
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	58	7
Construction in process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1
Furniture and vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 167	$ 155

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$ 159,000	$ 135,000

Other Assets - Summary of Other

Other Assets - Summary of Other Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Assets Noncurrent Disclosure [Line Items]
Prepaid rent and other assets	$ 63	$ 47
Total	63	886
IPO [Member]
Other Assets Noncurrent Disclosure [Line Items]
Deferred costs related to the initial public offering		$ 839
Total	$ 800

Other Current Liabilities - Sum

Other Current Liabilities - Summary of Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Liabilities Current [Abstract]
Costs related to the initial public offering		$ 327
Accrued professional fees	$ 33	20
Accrued payroll related and bonuses	307	114
Accrued utilities and outside services	90	137
Accrued other expense	61	56
Income Tax Payable	44	28
Deferred Tax Liability	34	9
Total	$ 569	$ 700

Loss per Share - Schedule of Ca

Loss per Share - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Basic and diluted net loss per share
Net loss	$ (3,349)	$ (4,900)	$ (5,319)	$ (4,593)	$ (2,946)	$ (3,052)	$ (6,894)	$ (2,772)	$ (18,161)	$ (15,664)
Net loss allocated to common shareholders									$ (18,161)	$ (15,664)
Weighted average shares outstanding - basic and diluted	13,335,188	13,334,503	13,333,334	11,759,260	9,166,667	9,166,667	9,166,667	9,166,667	12,945,968	9,166,667
Basic and diluted net loss per share	$ (0.25)	$ (0.37)	$ (0.40)	$ (0.39)	$ (0.32)	$ (0.33)	$ (0.75)	$ (0.30)	$ (1.40)	$ (1.71)

Loss per Share - Additional Inf

Loss per Share - Additional Information (Detail) - shares	Jan. 14, 2015	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Weighted average shares outstanding - basic and diluted		13,335,188	13,334,503	13,333,334	11,759,260	9,166,667	9,166,667	9,166,667	9,166,667	12,945,968	9,166,667
Antidilutive securities, not included in diluted net loss per calculation										1,044,743	0
2015 Capital Contribution [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Number of ordinary shares, shares issued	9,166,667										9,166,667
Weighted average shares outstanding - basic and diluted											9,166,667

Shareholders' Deficit - Additio

Shareholders' Deficit - Additional Information (Detail) $ / shares in Units, $ in Thousands	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2015€ / shares	Jan. 14, 2015shares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2014€ / shares
Equity [Abstract]
Deferred Ordinary shares | $	$ 54			$ 54
Deferred ordinary shares, par value | (per share)	$ 1.35	€ 1		$ 1.35	€ 1
Deferred ordinary shares, shares authorized	39,994			40,000
Deferred ordinary shares, shares issued	39,994		40,000	40,000

Stock Options - Additional Info

Stock Options - Additional Information (Detail) - USD ($)

Aug. 03, 2015

Feb. 28, 2015

Feb. 03, 2015

Jan. 14, 2015

Feb. 06, 2014

May. 31, 2015

Oct. 31, 2013

Oct. 31, 2010

Jun. 30, 2015

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Options granted

1,110,500

Share-based compensation expense

$ 2,150,000

Share-based compensation

$ 2,306,000

$ 313,000

Weighted average probability, concluded value of ordinary per share

$ 0.40

IPO [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Initial public offering, net of issuance costs, shares

4,166,667

Income Approach [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Weighted average probability

10.00%

Weighted average probability, per share

$ 1.06

Approach consisted of base case scenario

70.00%

Application of discount rate

27.50%

Weighted average discount rate projection period

10 years

Additional discount rate for lack of marketability of parents ordinary shares

22.00%

Income Approach [Member] | Delayed Case [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Additional probability percentage for cases

25.00%

Period of delay to enter market

1 year

Income Approach [Member] | Pessimistic Case [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Additional probability percentage for cases

5.00%

Market Approach [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Weighted average probability

90.00%

Weighted average probability, per share

$ 0.33

Market Approach [Member] | IPO [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Weighted average probability, per share

$ 0.42

Market Approach [Member] | Minimum [Member] | IPO [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Range of pre-IPO equity valuation

$ 90,000,000

Market Approach [Member] | Maximum [Member] | IPO [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Range of pre-IPO equity valuation

140,000,000

Presbia Holdings [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Award expiration date

Jun. 15, 2015

Share-based compensation expense

$ 156,000

$ 313,000

Incremental stock-based compensation expense

$ 21,000

Initial public offering, net of issuance costs, shares

9,666,667

40,000

9,666,667

9,666,667

Presbia Holdings [Member] | IPO [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Initial public offering, net of issuance costs, shares

500,000

500,000

Non-employee consultants and medical advisors [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Options granted

78,000

Employee options [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Options granted

1,032,500

Weighted average grant date fair value

$ 6.74

Unrecognized compensation expense related to options

$ 4,600,000

Unrecognized compensation expense, weighted average period of recognition

3 years 8 months 12 days

Non-employee options [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Percentage of estimated forfeiture rate

5.00%

Unrecognized compensation expense related to options

$ 4,600,000

Unrecognized compensation expense, weighted average period of recognition

3 years 8 months 12 days

Restricted shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Restricted shares, granted

29,559

Restricted shares, vested

1,854

Restricted shares, cancelled

7,416

Restricted shares outstanding

400,000

20,289

Weighted average grant date fair value

$ 7.89

Share-based compensation expense

$ 38,400

Unrecognized compensation expense, weighted average period of recognition

4 years 8 months 12 days

Unrecognized compensation expense related to restricted shares

$ 124,000

Restricted share grant fair value

$ 0.26

Share-based compensation

$ 104,000

Incremental stock-based compensation expense

$ 0

Restricted shares [Member] | Zohar Loshitzer [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Awards vesting period

3 years

Restricted shares, granted

1,000,000

Share-based compensation expense

$ 300,000

Issuance of restricted stock, shares

1,000,000

Restricted shares [Member] | Board Member 1 [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Restricted shares, granted

250,000

Restricted shares [Member] | Board Member 2 [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Restricted shares, granted

250,000

Restricted shares [Member] | Board members and president [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Restricted shares outstanding

400,000

Restricted share grant fair value

$ 0.30

Restricted shares [Member] | Board members [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Awards vesting period

5 years

Generally vesting percentage for annual

20.00%

Employee Stock Awards [Member] | Presbia Holdings [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Awards vesting period

10 years

Award expiration period

5 years

Over five year period [Member] | Employee Stock Awards [Member] | Presbia Holdings [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Generally vesting percentage for annual

20.00%

Presbia Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Awards vesting period

5 years

Ordinary shares authorized for issuance

1,800,000

Ordinary shares available for future grants and awards

693,000

Award expiration period

10 years

Award expiration date

Jan. 14, 2025

Presbia Incentive Plan [Member] | Over five year period [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Generally vesting percentage for annual

20.00%

Stock Options - Schedule of Opt

Stock Options - Schedule of Option Activity (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of shares, Granted | shares	1,110,500
Number of shares, Forfeited/cancelled | shares	(25,917)
Number of shares, Ending Balance | shares	1,084,583
Number of shares, Vested and expected to vest | shares	1,001,134
Number of shares, Exercisable | shares	90,000
Weighted average exercise price per share, Granted | $ / shares	$ 9.71
Weighted average exercise price per share, Forfeited/cancelled | $ / shares	8.98
Weighted average exercise price per share, Ending Balance | $ / shares	9.73
Weighted average exercise price per share, Vested and expected to vest | $ / shares	9.73
Weighted average exercise price per shares, Exercisable | $ / shares	$ 10
Presbia Holdings [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of shares, Beginning balance | shares	4,835,000
Number of shares, Exercised | shares	(3,860,000)
Number of shares, Forfeited/cancelled | shares	(975,000)
Weighted average exercise price per share, Beginning Balance | $ / shares	$ 0.11
Weighted average exercise price per share, Exercised | $ / shares	0.08
Weighted average exercise price per share, Forfeited/cancelled | $ / shares	$ 0.24
Aggregate intrinsic value, Exercisable | $	$ 656

Stock Options - Schedule of Bla

Stock Options - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Volatility minimum	69.80%
Volatility maximum	84.60%
Risk-free rate minimum	1.30%
Risk-free rate maximum	2.00%
Employee options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 4.39
Expected term	5 years 6 months
Employee options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 10
Expected term	6 years 6 months
Non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 5.26
Volatility minimum	75.80%
Volatility maximum	78.80%
Risk-free rate maximum	2.30%
Non-employee options [Member] | Presbia Holdings [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share		$ 0.40
Expected term		8 years 9 months 18 days
Volatility		77.00%
Risk-free rate		2.10%
Non-employee options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Expected term	9 years 2 months 12 days
Non-employee options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Expected term	9 years 10 months 24 days

Stock Options - Schedule of Res

Stock Options - Schedule of Restricted Share Activity (Detail) - Restricted shares [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested number of shares, Granted | shares	29,559
Unvested number of shares, Vested | shares	(1,854)
Unvested number of shares, Forfeited/cancelled | shares	(7,416)
Unvested number of shares, Ending Balance | shares	20,289
Unvested number of shares, Vested and expected to vest | shares	19,935
Unvested number of shares, Vested | shares	1,854
Weighted average fair value per share, Granted | $ / shares	$ 8.12
Weighted average fair value per share, Vested | $ / shares	8.63
Weighted average fair value per share, Forfeited/cancelled | $ / shares	8.63
Weighted average fair value per share, Ending Balance | $ / shares	7.89
Weighted average fair value per share, Vested and expected to vest | $ / shares	7.83
Weighted average fair value per shares, Vested | $ / shares	$ 8.63

Stock Options - Schedule of Sha

Stock Options - Schedule of Share-based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 2,150
Presbia Holdings [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	156	$ 313
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	223
Research and development [Member] | Presbia Holdings [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	28	213
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	1,762
General and administrative [Member] | Presbia Holdings [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	117	81
Sales and marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	165
Sales and marketing [Member] | Presbia Holdings [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 11	$ 19

Related Party Transactions - Sc

Related Party Transactions - Schedule of Amounts Due to Related Parties (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Payable to related parties-current:
Total	$ 55	$ 12
Payable due to the Parent-noncurrent:
Total		417
The Parent [Member]
Payable due to the Parent-noncurrent:
Principal amounts due to the Parent		417
Management services [Member]
Payable to related parties-current:
Management services provided by related parties	$ 55	$ 12

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Aug. 03, 2015	Feb. 28, 2015	Feb. 03, 2015	Jan. 14, 2015	Nov. 30, 2014	Feb. 06, 2014	Jul. 31, 2015	Jan. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Nov. 25, 2014
Related Party Transaction [Line Items]
Net principal amount due										$ 400,000
Accumulated funding outstanding percentage											15.00%
Accrued interest due										2,200,000
Aggregate funding from parent										1,558,000
Payable due to the Parent										417,000
Capitalization of amounts due to Parent per 2014 and 2015 Debt Conversions				$ 1,600,000	$ 23,500,000			$ 1,600,000	$ 1,559,000	23,473,000
Payment of bonus							$ 183,000
Due to related parties									55,000	12,000
Orchard Capital Corporation [Member]
Related Party Transaction [Line Items]
General and administrative expense									139,000	18,000
Orchard Capital Corporation [Member] | Management and Accounting Services [Member]
Related Party Transaction [Line Items]
Due to related parties									2,000	23,000
C I M Group L P
Related Party Transaction [Line Items]
Due to related parties									53,000	12,000
Charges incurred									$ 185,000	$ 152,000
Presbia Holdings [Member]
Related Party Transaction [Line Items]
Initial public offering, net of issuance costs, shares	9,666,667					40,000			9,666,667	9,666,667
IPO [Member]
Related Party Transaction [Line Items]
Initial public offering, net of issuance costs, shares			4,166,667
IPO [Member] | Presbia Holdings [Member]
Related Party Transaction [Line Items]
Initial public offering, net of issuance costs, shares		500,000	500,000
2015 Capital Contribution [Member]
Related Party Transaction [Line Items]
Initial public offering, net of issuance costs, shares								9,166,667
2014 Debt Conversion [Member]
Related Party Transaction [Line Items]
Conversion of debt to capital					$ 23,500,000

Operating Segments and Geogra53

Operating Segments and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015CustomerSegment	Dec. 31, 2014Customer
Segment Reporting Revenue Reconciling Item [Line Items]
Number of reportable segments | Segment	1
Number of customers	6	4
Supplier agreement term	5 years
Sales [Member] | Customer Concentration [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Concentration risk, percentage	100.00%	100.00%
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Concentration risk, percentage	100.00%
Maximum [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Number of customers	1

Operating Segments and Geogra54

Operating Segments and Geographic Information - Schedule of Revenues Generated from External Customers and Long-lived Assets by Area (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 28	$ 10	$ 42	$ 73	$ 36	$ 38	$ 61	$ 26	$ 153	$ 161
Long Lived Assets	775				747				775	747
Australia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									2
Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									9	4
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									67	149
Italy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues										4
Japan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues										4
South Korea [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									44
The Netherlands [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									29
UK [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									2
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	736				716				736	716
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	$ 39				$ 31				$ 39	$ 31

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - Facility Leases [Member] - USD ($)	May. 31, 2012	Dec. 31, 2015	Dec. 31, 2014
Commitments And Contingencies [Line Items]
Rent expense		$ 209,000	$ 234,000
California [Member]
Commitments And Contingencies [Line Items]
Non-cancelable lease term	5 years
Lease expiration period	May 31, 2017
Ireland [Member]
Commitments And Contingencies [Line Items]
Lease period	1 year
Lease commencement date	Dec. 1, 2013
Lease renewal term		1 month
The Netherlands [Member]
Commitments And Contingencies [Line Items]
Lease period	30 months
Lease commencement date	Jan. 1, 2016
Sub Lease Agreement [Member] | California [Member]
Commitments And Contingencies [Line Items]
Lease expiration period	Jul. 31, 2016
Lease period	26 months
Lease commencement date	Jun. 30, 2014

Commitment and Contingencies -

Commitment and Contingencies - Annual Base Rental Cost Over the Term of the Leases (Detail) - Facility Leases [Member] $ in Thousands	Dec. 31, 2015USD ($)
Operating Leased Assets [Line Items]
2,016	$ 178
2,017	63
2,018	7
2,019	0
2,020	0
2021 and Thereafter	0
Total	$ 248

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision for Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended							12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Current provision:
Federal								$ 0	$ 0
State								3	2
Foreign								16	8
Total current								19	10
Deferred provision
Federal								(306)	(90)
State								0	0
Foreign								(1,574)	(886)
Total deferred								(1,880)	(976)
Valuation allowance								1,880	976
Total deferred								0	0
Total income tax provision	$ 1	$ 9	$ 4	$ 5	$ 5	$ 3	$ 2	$ 19	$ 10

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Federal Statutory Rate to Effective Rate (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Expected income tax benefit at federal statutory rate	35.00%	35.00%
State tax provision, net of federal benefit	0.00%	0.00%
Foreign rate differential	(25.00%)	(24.00%)
Pass-through entities	(0.00%)	(0.00%)
Change in valuation allowance	(10.00%)	(6.00%)
Nondeductible expenses	0.00%	(5.00%)
Other	0.00%	0.00%
Income tax provision	0.00%	(0.10%)

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating loss carryforwards	$ 3,072	$ 1,201
Accrued expenses	27	44
Stock based compensation	241	186
Deferred tax assets	3,340	1,431
Valuation allowance	(3,247)	(1,366)
Net deferred tax assets	93	65
Deferred tax liabilities:
Depreciation	(93)	(65)
Total deferred tax liabilities	$ (93)	$ (65)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax [Line Items]
Operating loss carryforwards	$ 1,618,000	$ 729,000
Operating loss carryforwards expiration year	2,033
Operating Loss Carryforwards, Limitations on Use	NOL carryforwards may be limited in the event a cumulative change in ownership of 50% of certain shareholders occurs within a three-year period
Unrecognized tax benefits	$ 0	0
Accrued interest and penalties	0	0
Excess tax benefit from stock-based compensation.	39,000	39,000
Ireland [Member]
Income Tax [Line Items]
Operating loss carryforwards	$ 20,200,000	$ 7,600,000

Quarterly Financial Data (una61

Quarterly Financial Data (unaudited) - Summary of Unaudited Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 28	$ 10	$ 42	$ 73	$ 36	$ 38	$ 61	$ 26	$ 153	$ 161
Cost of goods sold	68	34	14	47	16	6	33	6	163	61
Operating expenses:
Research and development	1,324	2,333	2,502	1,776	820	1,016	1,675	732	7,935	4,243
Sales and marketing	593	760	834	519	546	463	394	249	2,706	1,652
General and administrative	1,391	1,762	2,007	2,319	1,048	881	4,272	1,376	7,479	7,577
Operating loss	(3,348)	(4,879)	(5,315)	(4,588)	(2,394)	(2,328)	(6,313)	(2,337)	(18,130)	(13,372)
Interest expense					552	719	584	433
Other (income) expense		12					(6)		12	(6)
Loss before income tax provision	(3,348)	(4,891)	(5,315)	(4,588)	(2,946)	(3,047)	(6,891)	(2,770)	(18,142)	(15,654)
Income tax provision	1	9	4	5		5	3	2	19	10
Net loss	$ (3,349)	$ (4,900)	$ (5,319)	$ (4,593)	$ (2,946)	$ (3,052)	$ (6,894)	$ (2,772)	$ (18,161)	$ (15,664)
Net loss per share - basic and diluted	$ (0.25)	$ (0.37)	$ (0.40)	$ (0.39)	$ (0.32)	$ (0.33)	$ (0.75)	$ (0.30)	$ (1.40)	$ (1.71)
Weighted average, shares outstanding - basic and diluted	13,335,188	13,334,503	13,333,334	11,759,260	9,166,667	9,166,667	9,166,667	9,166,667	12,945,968	9,166,667

Quarterly Financial Data (una62

Quarterly Financial Data (unaudited) - Summary of Unaudited Financial Data (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Write-off of deferred offering costs	$ 3,400	$ 3,369

Subsequent Events - Additional

Subsequent Events - Additional information (Detail) - Subsequent Event [Member] - Dr. Gerald Farrell [Member]	Jan. 19, 2016$ / sharesshares
Subsequent Event [Line Items]
Stock units awarded | shares	15,968
Stock price per share | $ / shares	$ 5.01

Consolidated Valuation and Qual

Consolidated Valuation and Qualifying Accounts (Detail) - Deferred Income Tax Asset Valuation Allowance [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 262
Additional Allowance	1,045
Adjustments	68
Balance at End of Period	$ 1,375